Polycomb Complex Group Gene Mutations and Their Prognostic Relevance In 5-Azacitidine Treated Myelodysplastic Syndrome Patients

被引：0

作者：

Kulasekararaj, Austin G. ^{[1
]}

Mohamedali, Azim M. ^{[2
]}

Smith, Alexander E. ^{[2
]}

Lea, Nicholas C. ^{[2
]}

Kizilors, Aytug ^{[2
]}

Abdallah, Atiyeh ^{[1
]}

Nasser, Erik E. ^{[2
]}

Mian, Syed A. ^{[2
]}

Yiu, Richard ^{[1
]}

Gaken, Joop ^{[2
]}

Pomplun, Sabine ^{[2
]}

Jiang, Jie ^{[1
]}

Gaymes, Terry J. ^{[2
]}

Pasipanodya, Patience ^{[1
]}

Hayden, Janet ^{[1
]}

Ireland, Robin M. ^{[1
]}

Lim, ZiYi ^{[1
]}

Ho, Aloysius Y. ^{[1
]}

Marsh, Judith C. W. ^{[1
]}

Mufti, Ghulam J. ^{[2
]}

机构：

[1] Kings Coll Hosp, Dept Haematol Med, London, England

[2] Kings Coll London, Dept Haematol Med, London WC2R 2LS, England

来源：

BLOOD | 2010年 / 116卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：61 / 61

页数：1

共 50 条

[41] Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
Itzykson, R.
Thepot, S.
Eclache, V.
Quesnel, B.
Dreyfus, F.
Beyne-Rauzy, O.
Turlure, P.
Vey, N.
Recher, C.
Boehrer, S.
Gardin, C.
Ades, L.
Fenaux, P.
LEUKEMIA, 2011, 25 (07) : 1207 - 1209
[42] Prognostic significance of monosomal karyotype in higher risk myelodysplastic syndrome treated with azacitidine
R Itzykson
S Thépot
V Eclache
B Quesnel
F Dreyfus
O Beyne-Rauzy
P Turlure
N Vey
C Recher
S Boehrer
C Gardin
L Adès
P Fenaux
Leukemia, 2011, 25 : 1207 - 1209
[43] COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
de Miguel, D.
Golbano, N.
San Roman, I.
Arbeteta, J.
Diaz, M.
Morales, D.
Herrero, S.
Subira, D.
PInedo, B.
HAEMATOLOGICA, 2012, 97 : 581 - 581
[44] THE MDS/MPN PATIENTS TREATED WITH 5-AZACITIDINE: A CLINICAL REAL LIFE EXPERIENCE
Riva, M.
Molteni, A.
Borin, L.
Bernardi, M.
Pellizzari, A.
Freyrie, A.
Della Porta, M.
Nichelatti, M.
Ravano, E.
Quaresmini, G.
Mariotti, J.
Caramazza, D.
Ubezio, M.
Guarco, S.
Gigli, F.
Greco, R.
Cairoli, R.
HAEMATOLOGICA, 2015, 100 : 725 - 725
[45] SINGLE INSTITUTION EXPERIENCE OF 5-AZACITIDINE THERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND ACUTE MYELOID LEUKEMIA
Freyrie, A.
Guidotti, F.
Reda, G.
Binda, F.
Cortelezzi, A.
HAEMATOLOGICA, 2012, 97 : 587 - 587
[46] 5-AZACITIDINE TREATMENT RESTORES RESPONSE TO EPOETIN THERAPY IN HIGH RISK MYELODYSPLASTIC (MDS) PATIENTS
Volpe, M.
Volpe, A.
HAEMATOLOGICA, 2012, 97 : 588 - 589
[47] COMPASIVE USE OF 5-AZACITIDINE IN PATIENTS WITH LOW/INT-1 RISK MYELODYSPLASTIC SYNDROMES
Dunia, D. M.
Nuria, G.
Miguel, D.
Jaime, A.
Helga, G.
Dolores, S.
Dolores, M.
Blanca, P.
Cristina, F.
Alejandro, V.
Sonia, H.
HAEMATOLOGICA, 2016, 101 : 773 - 774
[48] RESPONSE TO 5-AZACITIDINE IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES AND SECUNDARY AML: RESULTS FROM UNIQUE HOSPITAL
De Miguel, M. D.
Golbano, N.
San Roman, M. I. Lopez
Morfa, M. Diaz
Arbeteta, J.
Morales, D.
Pinedo, B.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 567 - 567
[49] THERAPY-RELATED MYELODYSPLASTIC SYNDROME: AN ANALYSIS OF 5 RISK MODELS IN PATIENTS TREATED WITH AZACITIDINE
Duong, V.
Lancet, J.
Al-Ali, N.
List, A.
Komrokji, R.
HAEMATOLOGICA, 2012, 97 : 368 - 369
[50] MUTATIONS OF COHESIN COMPLEX GENES IN MYELODYSPLASTIC SYNDROME: DISTINCT CLINIC-BIOLOGICAL FEATURES AND PROGNOSTIC RELEVANCE
Chen, L. H.
Hou, H. A.
Chou, W. C.
Kuo, Y. Y.
Tang, J. L.
Liu, C. Y.
Lin, C. C.
Tseng, M. H.
Chiang, Y. C.
Liu, M. C.
Liu, C. W.
Lin, L. I.
Tsay, W.
Yao, M.
Li, C. C.
Huang, S. Y.
Ko, B. S.
Hsu, S. C.
Chen, C. Y.
Lin, C. T.
Wu, S. J.
Tien, H. F.
HAEMATOLOGICA, 2016, 101 : 71 - 72

← 1 2 3 4 5 →